IL-2 LIPSOMES AS DELIVERY AGENTS FOR IMMUNOTHERAPEUTICS

描述：（改编自申请人的摘要）Vestar开发了 脂质体药物递送系统，其包含包封在脂质体中的（MTX）， 小单层囊泡内部水空间与人 重组IL-2共价偶联到外表面。 复杂 称为SUV-MTX-IL-2（SMI）。 它的设计目标是高 参与异常活化T细胞的亲和力IL-2受体 移植排斥和几种自身免疫性疾病 体外研究 在维斯塔的研究表明， 人PBL由于IL-2的存在而增殖，然后抑制 由于（MTX）的存在，增殖T细胞的进一步生长 运输到细胞质中。 这项研究的目的是为了证明 SMI抑制抗原特异性T细胞的生长， 恶唑烷酮诱导的大鼠迟发性超敏反应。SMI是 采用旨在保护IL-2受体的新技术制备 IL-2上的结合结构域，并且所使用的方法可以扩大到 制备无菌SMI，其在 存储. 商业目标是开发脂质体产品 其将抗增殖药物靶向免疫系统中不需要的细胞， 系统，同时最大限度地减少毒性，目前与 免费药物

DESCRIPTION: (Adapted from the applicant's abstract) Vestar has developed a liposomal drug delivery system comprised of (MTX) encapsulated in the internal aqueous space of small unilamellar vesicles and human recombinant IL-2 covalently coupled to the exterior surface. The complex is called SUV-MTX-IL-2 (SMI). It is designed to target to the high affinity IL-2 receptor of aberrantly activated T cells that participate in graft rejection and several autoimmune disorders. In vitro studies at Vestar has shown that this drug delivery system primes activated human PBL to proliferate due to the IL-2 present and then inhibits further growth of proliferating T cells due to the presence of (MTX) transported into the cytoplasm. The goal of this study will be to show that SMI inhibits the growth of antigen-specific T cells in oxazolanone-induced delayed hypersensitivity produced in rats. SMI is prepared with a novel technology designed to protect the IL-2 receptor binding domain on IL-2, and the methodologies used can be scaled up to prepare sterile SMI which exhibits adequate stability during storage. The commercial objective is to develop a liposomal product which targets an antiproliferative drug to unwanted cells of the immune system while minimizing the toxicity that is currently associated with the free drug.